COVABIND JOINT RESEARCH PRIVATE LIMITED

In their own words

Drug discovery is a constantly evolving process with multiple steps with several scientific disciplines in the medley. Covabind Joint Research Private Limited aims to facilitate and accelerate this process by offering broad range of services from target validation, hit identification, hit to lead and lead optimisation up to a clinically viable drug candidate. Most diseases, popularly cancer, are caused due to production of abnormal proteins by the body. Recent strategies developed to combat against such diseases are aimed at integrating the abnormal protein to the cell's natural degradation process aided by the Ubiquitin Proteosome System. One such accelerating field is the small molecule compounds designed to bind to the disease-causing proteins with high degree of specificity and guide them to the programmed degradation. Our researchers with their extensive experience in this arena are dedicated to developing lead drug candidates for cancer therapy and subsequently expand the strategy to developing treatment for other diseases. We are an eminent group of chemists and biologists with extensive experience in multiple aspects of the drug discovery process offering their expertise to assist you in your journey of developing your lead drug candidate. We aspire to lead chemistry-driven projects and also support, participate, and collaborate in relevant projects.On top of the discovery work, Covabind Joint Research Private Limited offers service in assessment of structure activity relationship (SAR and Quantitative-SAR), license-in and license-out compounds, logical selection of compounds or libraries for commercial development, stability studies for the active pharmaceutical ingredient (API), characterization of the API and impurities, production and formulation of the API and assistance in writing research grants. Covabind Joint Research yearns to deliver quality products, technology and services that can compare with international standards yet indigenous at its heart.

Written by the company on its public Startup India profile. Not verified by us.